<DOC>
	<DOCNO>NCT02723994</DOCNO>
	<brief_summary>This nonrandomized study ruxolitinib combination standard multi-agent chemotherapy regimen treatment B-cell acute lymphoblastic leukemia . Part 1 study optimize dose study drug ( ruxolitinib ) combination chemotherapy regimen . Part 2 evaluate efficacy combination chemotherapy ruxolitinib recommend dose determine Part 1 .</brief_summary>
	<brief_title>A Phase 2 Study Ruxolitinib With Chemotherapy Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>De novo highrisk ( HR ) Phlike BALL follow criterion present diagnosis : Age ≥ 10 year White blood cell ( WBC ) ≥ 50 × 10^3/μL CNS3 leukemia One follow Phlike ALL genetic lesion must present diagnostic bone marrow peripheral blood sample : CRLF2 rearrangement JAK1 JAK2 mutation ( JAK+ ) CRLF2 rearrangement without JAK mutation Other JAK pathway alteration ( eg , JAK2 fusion , erythropoietin receptor ( EPOR ) fusion , SH2B3 deletion , interleukin7 receptoralpha ( IL7RA ) mutation ) without CRLF2 rearrangement Completed 4drug Induction therapy regimen ( modify aBFM regimen equivalent ) Study AALL1131 institutional standard care HR BALL endInduction minimal residual disease ( MRD ) assess Male female subject reproductive non childbearing potential willing take appropriate precaution avoid pregnancy father child duration study participation Receipt cytotoxic chemotherapy Induction therapy , exception hydroxyurea steroid pretreatment Trisomy 21 ( Down syndrome ) BCRABL1rearranged ( Ph+ ) ALL Calculated creatinine clearance radioisotope glomerular filtration rate &lt; 70 mL/min/1.73 m^2 Alanine aminotransferase ≥ 3 × upper limit normal ( ULN ) age Direct bilirubin ≥ 1.5 × ULN ( may assume total bilirubin ULN ) History evidence cirrhosis Platelet count &lt; 75 × 10^3/μL Absolute neutrophil count ( ANC ) &lt; 750/μL Positive screen hepatitis B C Known human immunodeficiency virus infection</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>B-cell acute lymphoblastic leukemia ( ALL )</keyword>
	<keyword>pediatric</keyword>
	<keyword>multi-agent chemotherapy</keyword>
	<keyword>JAK inhibitor</keyword>
</DOC>